With new leadership and a Nasdaq relisting plan, the iconic brand is betting on women’s health and weight loss drugs to stage ...

Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects. Read why NVO stock is a ...

Analyst initiates coverage of WeightWatchers with a buy rating after bankruptcy reemergence. IPO hot streak continues.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...